<DOC>
	<DOCNO>NCT02439957</DOCNO>
	<brief_summary>â€¢ To compare efficacy brincidofovir ( BCV ) valganciclovir ( vGCV ) prevention CMV disease kidney transplant recipient CMV seropositive pretransplant receive antilymphocyte induction therapy</brief_summary>
	<brief_title>SURPASS : A Randomized , Double-Blind , Multicenter Study Efficacy , Safety , Tolerability Brincidofovir Versus Valganciclovir Prevention Cytomegalovirus ( CMV ) Disease CMV Seropositive Kidney Transplant Recipients ( BCV CMV vGCV )</brief_title>
	<detailed_description />
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>CMV seropositive ( R+ ) , receive antilymphocyte induction therapy antithymocyte globulin ( ATG ) First second kidney transplant recipient 14 day posttransplant eGFR &gt; 10mL/min CG equation Able ingest tablet Multi organ transplant recipient Plasma CMV PCR &gt; LOD central lab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>